RxDoctor Payments Data

Joanne Francis, MD

Ophthalmology · Palm Coast, FLNPI 1588185391

Payments from drug & device makers

$3,377in general payments, 2019–2025

Across 103 payments — averaging $32.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$474
  • Alcon$441
  • Dompe US, Inc.$435
  • Oyster Point Pharma, Inc.$307
  • Biotissue Holdings Inc.$272
  • Bausch & Lomb Americas Inc.$246
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,377 in reported general payments places this provider in the 60th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$107,946
Medicare patients
420
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj11$317,957
RestasisCyclosporine28$34,408
XiidraLifitegrast23$22,537
MieboPerfluorohexyloctane/Pf26$20,829
Prednisolone Acetate211$9,059
Loteprednol Etabonate29$5,518
MoxifloxacinMoxifloxacin Hcl157$4,810
Lotemax SmLoteprednol Etabonate14$3,605
ValacyclovirValacyclovir Hcl32$3,033
Ketorolac Tromethamine58$2,322
Doxycycline Hyclate20$605
Latanoprost48$264
Brimonidine Tartrate16$263
Dorzolamide Hcl11$225
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$435$317,95711 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$246$43,36649 claims
AbbVieRestasis$218$34,40828 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm$31$9,12443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →